TAO Synergies Inc. (TAOX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TAO Synergies Inc. (formerly Synaptogenix, Inc.) on June 27, 2025, covering events occurring on June 8, 2025, and June 26, 2025. The filing serves two primary purposes: correcting a prior statement regarding the status of a former CEO and announcing a formal corporate name change.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or liquidity data. The only financial metric disclosed relates to executive compensation:
- Executive Compensation Adjustment: Dr. Alan J. Tuchman's base monthly salary was reduced to $7,500 per month following his resignation as CEO.
Material Changes
The filing details two significant corporate actions:
- Correction of Prior Filing: The Company corrected a June 9, 2025, report to clarify that while Dr. Alan J. Tuchman resigned as Chief Executive Officer effective June 8, 2025, he remains a member of the Board of Directors and has been appointed Chief Medical Officer.
- Corporate Name Change: Effective June 26, 2025, the Company changed its name from Synaptogenix, Inc. to TAO Synergies Inc. via an amendment to its Certificate of Incorporation.
- Trading Symbol Change: The Company anticipates that effective July 1, 2025, its Common Stock will cease trading under the ticker symbol "SNPX" and begin trading under the new ticker symbol "TAOX" on the Nasdaq Capital Market. The CUSIP number remains unchanged.
Outlook, Risks, and Management Commentary
Management confirmed that the name change and amendment were approved by the Board of Directors and did not require stockholder approval under Delaware General Corporation Law. The filing states that the name change will not affect the voting rights, validity, or transferability of the Company's Common Stock. No specific risks, contingencies, or forward-looking financial guidance were provided in this report.
Investor Verification Checklist
- Verify the effective date of the ticker symbol change from "SNPX" to "TAOX" on July 1, 2025.
- Confirm Dr. Alan J. Tuchman's current roles as Chief Medical Officer and Board Member.
- Review the attached Certificate of Amendment (Exhibit 3.1) for details on the name change.
- Note that this filing contains no financial performance data; refer to the most recent 10-Q or 10-K for financial metrics.